MoonLake Immunotherapeutics (MLTX) Form 424B5 — Jun 22, 2026
MoonLake Immunotherapeutics filed a prospectus supplement for a public offering of Class A Ordinary Shares and pre-funded warrants to purchase Class A Ordinary Shares. The company intends to use the net proceeds from this offering to fund the research, development, and potential commercialization of its lead candidate, Sonelokimab (SLK), targeting a potential launch in 2027, as well as for general corporate purposes. The underwriters, led by Leerink Partners and Guggenheim Securities, have been granted a 30-day option to purchase up to $22,500,000 of additional Class A Ordinary Shares at the public offering price.
Key figures
- Last Sale Price
- 22.16
- Greenshoe Value
- 22500000
- Offering Expenses
- 200000
- Shares Outstanding
- 72134066
- Atm Remaining Capacity
- 219500000
- Net Tangible Book Value
- 254000000
- Net Tangible Book Value Per Share
- 3.52
Price after filing
Close on the filing date to close N calendar days later (from $22.16). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.